Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics [Yahoo! Finance]
Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics
Molecular Partners (NASDAQ:MOLN) had its price target lowered by analysts at JPMorgan Chase & Co. from $4.00 to $3.75. They now have a "neutral" rating on the stock.
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
Molecular Partners (NASDAQ:MOLN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.